MEDIPOST obtained a patent in Canada for its Alzheimer’s disease treatment composition based on stem cells.
The title of this patent is ‘Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases’ and the patent covers the use of cord blood stem cells that secrete GDF-15 protein.
An official from MEDIPOST explained, “This patented technology is currently applied to the Alzheimer’s disease treatment drug, ‘NEUROSTEM®’ currently on clinical trials. It can also be used for treating cranial nerve disorders such as depression, epilepsy, multiple sclerosis and manic disorder.
MEDIPOST already has a similar patent in Korea, Singapore, Australia, UK, Mexico and Japan.